Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

An expanded high throughput RT-PCR assay to rapidly identify all known SARS-CoV-2 variants of concern using melting temperature coding

View ORCID ProfilePadmapriya P Banada, Raquel Green, Sukalyani Banik, Deanna Streck, View ORCID ProfileIbsen Montalvan, Robert Reiss, Robert Jones, View ORCID ProfileSalvatore A. E. Marras, View ORCID ProfileSoumitesh Chakravorty, View ORCID ProfileDavid Alland
doi: https://doi.org/10.1101/2022.01.18.22269424
Padmapriya P Banada
aPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Padmapriya P Banada
  • For correspondence: allandda@njms.rutgers.edu priya.banada@rutgers.edu
Raquel Green
aPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sukalyani Banik
aPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deanna Streck
bInstitute of Genomic Medicine, Rutgers New Jersey Medical School, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ibsen Montalvan
cUniversity Hospital, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ibsen Montalvan
Robert Reiss
dDivision of Infectious Diseases, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Jones
eCraic Computing LLC, Snohomish, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salvatore A. E. Marras
aPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Salvatore A. E. Marras
Soumitesh Chakravorty
aPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ
fCepheid, Sunnyvale, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Soumitesh Chakravorty
David Alland
aPublic Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Alland
  • For correspondence: allandda@njms.rutgers.edu priya.banada@rutgers.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The rapid emergence of new vaccine-resistant SARS-CoV-2 variants of concern (VOC) requires an equally rapid deployment of diagnostic tests to specifically identify each VOC as soon as it arises. Here, we report an expanded version of our previously described sloppy molecular beacon (SMB) Alpha/Beta/Gamma RT-PCR melting temperature (Tm) signature-based assay, which now includes modifications that allow specific detection of Delta (B.1.617.2) and Omicron (B.1.529) VOCs.

Methods We developed a dual SMB assay (SMB-452), which targeted the T22917G (L452R) mutation in the SARS-CoV-2 spike protein to specifically detect the Delta VOC. We also identified a Tm profile in our existing SMB-501 and SMB-484 assays (which detect mutations in codons 501 and 484 of the SARS-CoV-2 spike protein, respectively) that differentiate the Omicron-specific N501Y (A23063T) and E484A (A23013C) mutations from both wild type (WT) and other VOCs. The entire six SMB three-codon assay was tested using reference SARS-CoV-2 RNAs. The assay was then validated using clinical samples from COVID-19 patients tested with a LightCycler 480 (LC480) (74 samples), Bio-Rad CFX96 (34 samples), Rotor-Gene Q (Qiagen) (34 samples) and an ABI-7500 (34 samples) RT-PCR instruments. Six SMB Tm results were then inputted into an Excel Analysis tool to generate specific VOC identifications.

Results The limit of detection (LOD) for the new SMB-452 assay, which specifically identified the Delta variant was 1 genomic equivalent (GE) per reaction. The LODs of the SMB-501 and SMB-484 assays, which detect Omicron were 100 and 103 GE respectively. Clinical validation of the 3-codon assay in the LC480 instrument showed the assay detected 94% of the samples as WT or VOCs in clinical samples and 6% of the tests producing indeterminate results. None of the samples were incorrectly identified as WT or as a different VOC. Thus, excluding samples with indeterminant results, the assay was 100% sensitive and 100% specific compared to sequencing. There was also 100% concordance between the LC480, BioRad, ABI and Qiagen results, excluding negative or indeterminate results; however, the Qiagen assay had significantly more indeterminates than the other assays.

Conclusion This new assay can serve as a robust diagnostic tool for selecting appropriate monoclonal antibody therapy and rapid VOC surveillance.

Competing Interest Statement

D.A. receives research support and royalty payments from Cepheid, which sells the Xpert Xpress SARS-CoV-2 and Xpert Xpress SARS-CoV-2/Flu/RSV tests., S.C, is an employee of Cepheid and R.J. is a paid consultant for Cepheid.

Funding Statement

This study was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R01 AI131617

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The usage of de-identified clinical samples from RT-PCR confirmed COVID-19 positive and negative patients in this study was approved by the Rutgers University institutional Review Board under protocol numbers 20170001218 and 2020001541.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are contained in the manuscript and will also be available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted January 21, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
An expanded high throughput RT-PCR assay to rapidly identify all known SARS-CoV-2 variants of concern using melting temperature coding
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
An expanded high throughput RT-PCR assay to rapidly identify all known SARS-CoV-2 variants of concern using melting temperature coding
Padmapriya P Banada, Raquel Green, Sukalyani Banik, Deanna Streck, Ibsen Montalvan, Robert Reiss, Robert Jones, Salvatore A. E. Marras, Soumitesh Chakravorty, David Alland
medRxiv 2022.01.18.22269424; doi: https://doi.org/10.1101/2022.01.18.22269424
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
An expanded high throughput RT-PCR assay to rapidly identify all known SARS-CoV-2 variants of concern using melting temperature coding
Padmapriya P Banada, Raquel Green, Sukalyani Banik, Deanna Streck, Ibsen Montalvan, Robert Reiss, Robert Jones, Salvatore A. E. Marras, Soumitesh Chakravorty, David Alland
medRxiv 2022.01.18.22269424; doi: https://doi.org/10.1101/2022.01.18.22269424

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1947)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
  • Epidemiology (11102)
  • Forensic Medicine (8)
  • Gastroenterology (624)
  • Genetic and Genomic Medicine (3168)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12720)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2986)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1552)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2785)
  • Public and Global Health (5591)
  • Radiology and Imaging (1094)
  • Rehabilitation Medicine and Physical Therapy (635)
  • Respiratory Medicine (760)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)